Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients with irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864095/
https://www.ncbi.nlm.nih.gov/pubmed/31745135
http://dx.doi.org/10.1038/s41598-019-53327-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864095/
https://www.ncbi.nlm.nih.gov/pubmed/31745135
http://dx.doi.org/10.1038/s41598-019-53327-7

Ejemplares similares